It’s well known that the body’s energy levels cycle on a 24-hour, or circadian, schedule, and that this metabolic process is fueled by oxygen. Now, researchers at the School of Medicine have found that a protein called Rev-erb coordinates the daily cycles of oxygen-carrying heme molecules to maintain the body’s correct metabolism.
The research appears online this week in Science Express in advance of print publication in Science.
Many studies, including this one, point to a link between the human internal clock and such metabolic disorders as obesity and diabetes. Proteins such as Rev-erb are the gears of the clock and understanding their role is important for fighting these diseases.
“This is the next chapter on Rev-erb, a member of a family of cell-nucleus proteins that includes receptors for anti-diabetic drugs,” explains senior author Mitchell A. Lazar, MD, PhD, Director of the Institute for Diabetes, Obesity, and Metabolism at Penn. About two years ago Lazar’s group discovered that Rev-erb was a critical component of the circadian clock. In this paper, they found that the activity of Rev-erb is controlled by heme.
Heme represents the body's most important way of transporting and using oxygen, which would simply bubble away in the body without being bound to heme. “In a molecular baton hand-off, oxygen is transferred from heme in the bloodstream to the heme molecules found inside a cell,” says Lazar, of how oxygen reaches cells to run their metabolic needs. One of the most important roles of heme inside cells is to facilitate the use of oxygen to generate energy in the process known as cellular respiration.
The findings further tie together the 24-hour cycle of the body with metabolic function. “Circadian rhythms are our sleep-wake cycle and metabolism is how we process food, so it makes sense that there would be biological cross-talk between the body’s 24-hour rhythm and metabolic function,” says Lazar. Indeed, scientists already recognize that getting too much or too little sleep increases the risk of diabetes. The newly discovered circadian/metabolic link could be the focus of a new generation of diabetes treatments.
The Penn group worked with scientists at GlaxoSmithKline, who demonstrated that the Rev-erb protein can physically bind to heme in the test tube. The Penn scientists then found that heme, by regulating the activity of Rev-erb, reduces the amount of glucose produced by liver cells.
“What’s exciting about this is that it puts heme in a central role in the metabolic regulation of the cell,” says Lazar. “Not only is it a key component in making energy, but also in the pathway for turning off glucose production.” Excessive glucose production by the liver is a major cause of high blood sugar in diabetes.
This work was funded by the National Institute of Diabetes and Digestive and Kidney Disease. Co-authors are first author Lei Yin, Joshua C. Curtin, Mohammed Qatananai, and Nava R. Szwergold, all from Penn and Robert A. Reid, Gregory M. Waitt, Derek J. Parks, Kenneth H. Pearce, and G. Bruce Wisely, from GlaxoSmithKline, Research Triangle Park, NC.
This release is available at www.pennhealth.com/news
PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the nation in U.S. News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.